SG11201807779PA - Mixed salt compositions for producing elevated and sustained ketosis - Google Patents
Mixed salt compositions for producing elevated and sustained ketosisInfo
- Publication number
- SG11201807779PA SG11201807779PA SG11201807779PA SG11201807779PA SG11201807779PA SG 11201807779P A SG11201807779P A SG 11201807779PA SG 11201807779P A SG11201807779P A SG 11201807779PA SG 11201807779P A SG11201807779P A SG 11201807779PA SG 11201807779P A SG11201807779P A SG 11201807779PA
- Authority
- SG
- Singapore
- Prior art keywords
- bhb
- international
- mixed salt
- utah
- march
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 150000003839 salts Chemical class 0.000 title abstract 4
- 208000007976 Ketosis Diseases 0.000 title abstract 3
- 230000004140 ketosis Effects 0.000 title abstract 3
- 230000002459 sustained effect Effects 0.000 title abstract 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 abstract 5
- -1 BHB compound Chemical class 0.000 abstract 3
- 230000002361 ketogenic effect Effects 0.000 abstract 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003792 electrolyte Substances 0.000 abstract 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 102220547770 Inducible T-cell costimulator_A23L_mutation Human genes 0.000 abstract 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- 244000062793 Sorghum vulgare Species 0.000 abstract 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 229910002091 carbon monoxide Inorganic materials 0.000 abstract 1
- 125000002091 cationic group Chemical group 0.000 abstract 1
- 150000001768 cations Chemical class 0.000 abstract 1
- 230000001627 detrimental effect Effects 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 235000019634 flavors Nutrition 0.000 abstract 1
- 230000008821 health effect Effects 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 150000004667 medium chain fatty acids Chemical class 0.000 abstract 1
- 235000019713 millet Nutrition 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000011591 potassium Substances 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 229910052723 transition metal Inorganic materials 0.000 abstract 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 abstract 1
- 235000005282 vitamin D3 Nutrition 0.000 abstract 1
- 239000011647 vitamin D3 Substances 0.000 abstract 1
- 229940021056 vitamin d3 Drugs 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662307203P | 2016-03-11 | 2016-03-11 | |
| US15/454,157 US10292952B2 (en) | 2016-03-11 | 2017-03-09 | Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis |
| PCT/US2017/021886 WO2017156446A1 (fr) | 2016-03-11 | 2017-03-10 | Compositions de sel mixte permettant de produire une cétose élevée et prolongée |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201807779PA true SG11201807779PA (en) | 2018-10-30 |
Family
ID=59788008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201807779PA SG11201807779PA (en) | 2016-03-11 | 2017-03-10 | Mixed salt compositions for producing elevated and sustained ketosis |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10292952B2 (fr) |
| EP (1) | EP3426240B1 (fr) |
| CA (1) | CA3017361A1 (fr) |
| SG (1) | SG11201807779PA (fr) |
| WO (1) | WO2017156446A1 (fr) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11241403B2 (en) * | 2016-03-11 | 2022-02-08 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
| US10596131B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10596130B2 (en) | 2017-12-19 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
| US11185518B2 (en) | 2017-12-19 | 2021-11-30 | Axcess Global Sciences, Llc | S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer |
| US10973792B2 (en) | 2019-02-13 | 2021-04-13 | Axcess Global Sciences, Llc | Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use |
| US10245242B1 (en) * | 2017-11-22 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10245243B1 (en) * | 2017-12-19 | 2019-04-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
| US10596129B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10736861B2 (en) | 2016-03-11 | 2020-08-11 | Axcess Global Sciences, Llc | Mixed salt compositions for producing elevated and sustained ketosis |
| US11103470B2 (en) | 2017-11-22 | 2021-08-31 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| US10973786B2 (en) | 2016-03-11 | 2021-04-13 | Axcess Global Sciences, Llc | R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions |
| US11026929B2 (en) | 2016-04-19 | 2021-06-08 | Keto Patent Group, Inc. | Administration of berberine metabolites |
| WO2017184788A1 (fr) * | 2016-04-19 | 2017-10-26 | Keto Patent Group, Inc. | Administration de butyrate, de bêta-hydroxybutyrate et de composés apparentés à des humains |
| US20180057846A1 (en) | 2016-08-30 | 2018-03-01 | KetoneAid Inc. | Partially buffered free acid and/or ketone blend for rapid onset ketosis and metabolic therapy |
| US20180177753A1 (en) | 2016-12-23 | 2018-06-28 | Neuroenergy Ventures, Inc. | Glyceryl 3-hydroxybutyrates for migraine symptom management |
| US9925164B1 (en) | 2017-01-12 | 2018-03-27 | Neuroenergy Ventures, Inc. | Glyceryl 3-hydroxybutyrates for traumatic brain injury |
| CA3039255C (fr) * | 2017-04-04 | 2022-11-29 | NNB Nutrition USA, LLC | Preparation de l'acide (r)-3-hydroxybutyrique ou ses sels par fermentation en une etape |
| US11760963B2 (en) | 2017-08-23 | 2023-09-19 | KetoneAid Inc. | Ketogenic beer and alcoholic beverage mixture containing non-racemic ethyl 3-hydroxybutyrate and/or 1,3 butanediol |
| US11202769B2 (en) | 2017-11-22 | 2021-12-21 | Axcess Global Sciences, Llc | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function |
| US10925843B2 (en) * | 2018-04-18 | 2021-02-23 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
| US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
| US10980772B2 (en) | 2018-08-27 | 2021-04-20 | Axcess Global Sciences, Llc | Compositions and methods for delivering tetrahydrocannabinol and ketone bodies |
| US11129802B2 (en) | 2018-08-27 | 2021-09-28 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
| US11241401B2 (en) | 2020-02-06 | 2022-02-08 | Axcess Global Sciences, Llc | Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions |
| US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
| US11419836B2 (en) | 2019-02-13 | 2022-08-23 | Axcess Global Sciences, Llc | Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions |
| AU2020222897A1 (en) * | 2019-02-11 | 2021-09-02 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
| JP7448555B2 (ja) * | 2019-02-11 | 2024-03-12 | アクセス・グローバル・サイエンシーズ・エルエルシー | ラセミベータ－ヒドロキシブチレート混合塩－酸組成物および使用方法 |
| AU2020221031A1 (en) * | 2019-02-11 | 2021-09-02 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt-acid compositions and methods of use |
| EP3923926A4 (fr) * | 2019-02-11 | 2022-11-16 | Axcess Global Sciences, LLC | Composés de s-bêta-hydroxybutyrate et compositions enrichies en s-énantiomère |
| US20220338510A2 (en) * | 2019-03-14 | 2022-10-27 | Neuroenergy Ventures, Inc. | Taste-Masking Formulation For Ketone Body Compounds |
| US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| US11033553B2 (en) | 2019-06-21 | 2021-06-15 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
| RU2769242C1 (ru) * | 2021-06-16 | 2022-03-29 | Александр Владимирович Чемоданов | Кетогенная композиция |
| US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2238149A (en) * | 1937-11-02 | 1941-04-15 | Aeckerle Emil | Process for improving the stability of hygroscopic substances |
| AU6776887A (en) * | 1985-12-18 | 1987-07-15 | Veech, R.L. | Fluid therapy with l-lactate and/or pyruvate anions |
| US5116868A (en) * | 1989-05-03 | 1992-05-26 | The Johns Hopkins University | Effective ophthalmic irrigation solution |
| US6323237B1 (en) | 1997-03-17 | 2001-11-27 | Btg International Limited | Therapeutic compositions |
| US6316038B1 (en) | 1997-03-17 | 2001-11-13 | Btg International Limited | Therapeutic compositions |
| JPH1160434A (ja) | 1997-08-12 | 1999-03-02 | Kanebo Ltd | 皮膚老化防止化粧料 |
| JP2002524506A (ja) | 1998-09-15 | 2002-08-06 | ビーティージー・インターナショナル・リミテッド | 治療用組成物（ｉｉ） |
| DK1292294T3 (da) | 2000-05-01 | 2009-06-22 | Accera Inc | Anvendelse af mediumkæde-triglycerider til behandling og forebyggelse af Alzheimers sygdom |
| US6613356B1 (en) * | 2000-10-10 | 2003-09-02 | Victor Vlahakos | Weight loss medication and method |
| GB0410266D0 (en) | 2004-05-07 | 2004-06-09 | Ketocytonyx Inc | Treatment of apoptosis |
| US20070135376A1 (en) | 2005-06-20 | 2007-06-14 | Accera, Inc. | Method to reduce oxidative damage and improve mitochondrial efficiency |
| HUE035852T2 (en) | 2006-04-03 | 2018-05-28 | Accera Inc | Use of ketogen compounds to treat memory decline |
| WO2008005818A1 (fr) | 2006-06-30 | 2008-01-10 | Stepan Co | Esters glycéridiques pour le traitement de maladies associées à un métabolisme neuronal réduit du glucose |
| WO2008128095A1 (fr) | 2007-04-12 | 2008-10-23 | Regents Of The University Of Minnesota | Compositions de protection contre l'ischémie/reperfusion et procédés d'utilisation |
| AU2009204370B2 (en) | 2008-01-04 | 2014-12-04 | Gvmt Of The Usa, As Represented By The Secretary, Department Of Health & Human Services | Ketone bodies and ketone body esters as blood lipid lowering agents |
| PE20151949A1 (es) * | 2013-03-19 | 2016-01-05 | Univ South Florida | Composiciones y metodos para producir cetosis elevada y sostenida |
-
2017
- 2017-03-09 US US15/454,157 patent/US10292952B2/en active Active
- 2017-03-10 EP EP17764221.2A patent/EP3426240B1/fr active Active
- 2017-03-10 CA CA3017361A patent/CA3017361A1/fr active Pending
- 2017-03-10 WO PCT/US2017/021886 patent/WO2017156446A1/fr active Application Filing
- 2017-03-10 SG SG11201807779PA patent/SG11201807779PA/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017156446A1 (fr) | 2017-09-14 |
| CA3017361A1 (fr) | 2017-09-14 |
| EP3426240A4 (fr) | 2019-11-27 |
| US20170258745A1 (en) | 2017-09-14 |
| EP3426240A1 (fr) | 2019-01-16 |
| US10292952B2 (en) | 2019-05-21 |
| EP3426240B1 (fr) | 2024-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807779PA (en) | Mixed salt compositions for producing elevated and sustained ketosis | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201803529RA (en) | Lubricant compositions for surface finishing of materials | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201408769QA (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201805533QA (en) | Composition and methods for cryopreservation of hutc | |
| SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
| SG11201806267QA (en) | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | |
| SG11201811671XA (en) | Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof | |
| SG11201804770QA (en) | Method and arrangement for recovery of salt | |
| SG11201901501UA (en) | Compositions and methods for enhancing cancer radiotherapy | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201811416VA (en) | Crystalline solid forms of a bet inhibitor | |
| SG11201805387RA (en) | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists | |
| SG11201408808WA (en) | Method and system for treatment of biological tissue | |
| SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
| SG11201805649UA (en) | Therapeutic anti-cd9 antibody | |
| SG11201903327PA (en) | Crystalline forms of eravacycline | |
| SG11201900336YA (en) | Radioligands for imaging the ido1 enzyme | |
| SG11201803762RA (en) | High viscosity base stock compositions | |
| SG11201806286VA (en) | Whey protein based liquid nutritional composition |